IndustryCompany release

Teleflex Q3 revenue flat at $567.8m as it lifts 2026 adjusted EPS guidance

🇺🇸 Teleflex Inc (TFX) · Thu 05 Nov 2026

The medtech group also reports FDA Breakthrough Device Designation for its Freesolve magnesium scaffold and a completed OEM divestiture, with the Intersurgical sale still awaiting regulatory approval.

Teleflex reported third-quarter 2026 revenue from continuing operations of $567.8 million for the period ended 30 September, an increase of 0.2%. On a pro forma adjusted constant-currency basis, growth was 3.0%.

The company raised its 2026 adjusted earnings-per-share guidance to a range of $7.50 to $7.75. It left its constant-currency growth outlook unchanged.

On the regulatory front, Teleflex said the US Food and Drug Administration has granted Breakthrough Device Designation to Freesolve, its magnesium scaffold intended for percutaneous coronary intervention (PCI). The FDA programme is designed to speed review of devices for serious conditions, though the designation does not amount to marketing authorisation.

Teleflex also said it has repurchased $350 million of shares since 1 July and has completed the divestiture of its OEM business. A separate sale of its Acute Care and Interventional Urology businesses to Intersurgical remains pending, subject to regulatory approval.

What it means for your team

  • Regulatory teams tracking coronary devices should note the Breakthrough designation for Freesolve, which signals closer FDA interaction but not clearance or approval.
  • The Intersurgical transaction for Acute Care and Interventional Urology is still conditional on regulatory approval, so product ownership and responsibilities have not yet transferred.
  • Quality and market-access teams working with Teleflex's OEM-related products should expect changes in the supply and contracting landscape now that the OEM divestiture is complete.

Company's press release (SEC filing): Teleflex Inc ↗

Article written by VigiEye from the official source (Teleflex Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →